Celltrion Reports Q2 Revenue of 1.3T KRW, Up 35% as New Biosimilars Drive Growth

According to Asia Economy, on July 3, South Korean biopharmaceutical company Celltrion reported second-quarter earnings that exceeded market expectations. The company posted revenue of 1.3 trillion Korean won and operating profit of 430 billion won, representing year-over-year increases of 35.2% and 77.3%, respectively. Operating margin expanded to the mid-30% range.

The company's strong performance was driven by biosimilar products, with new medicines including Omriclone accounting for 58% of sales and pushing gross margins above 62%. Celltrion also benefited from U.S. contract manufacturing organization (CMO) revenue and contributions from a Lilly production facility acquired in December 2025. The company is expected to see accelerated growth in the second half of 2026, with plans to launch additional biosimilars in the U.S. market and advancing clinical-stage drug candidates.